Antagonists of HMG1 for treating inflammatory conditions
AssigneeNorth Shore-Long Island Jewish Research Institute
InventorsKevin J. Tracey, Haichao Wang
Life of this patent
Estimating the term…
Abstract
There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
Claims16
A pharmaceutical composition for treating conditions (diseases) characterized by activation of the inflammatory cytokine cascade, comprising an effective amount of an antagonist or inhibitor of HMG 1.
A method for treating a condition characterized by activation of the inflammatory cytokine cascade, comprising administering an effective amount of an HMG1 antagonist.
A diagnostic and prognostic method for monitoring the severity and predicting the likely clinical course of sepsis and related conditions for a patient exhibiting, shock-like symptoms or at risk to exhibit symptoms associated with conditions characterized by activation of the inflammatory cascade, comprising measuring the concentration of HMG1 in a sample, and comparing that concentration to a standard for HMG1 representative of a normal concentration range of HMG1 in a like sample, whereby higher levels of HMG1 are indicative of poor prognosis or the likelihood of toxic reactions.
A pharmaceutical composition for effecting weight loss or treating obesity, comprising an effective amount of HMG1 or a therapeutically active fragment thereof.
A method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active fragment thereof.
A pharmaceutical composition for treating sepsis and related conditions, comprising an effective amount of an HMG1 antagonist.
A method for treating sepsis and related conditions involving activation of the inflammatory cytokine cascade syndrome, comprising administering an effective amount of an HMG1 antagonist.
A diagnostic method for monitoring the diagnosing or monitoring the severity of sepsis Or septic shock, comprising measuring a serum concentration of HMG1 in a patient at risk to exhibit or exhibiting sepsis or septic shock-like symptoms, whereby higher levels of HMG1 are indicative Of a diagnosis of sepsis or septic shock or a poor prognosis.
Dependencies are inferred from the claim text.